Press Releases

Month Year

Investor Alerts

Aug 7, 2014

Karyopharm Therapeutics Reports Second Quarter Financial Results for 2014

NEWTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
Aug 7, 2014

Karyopharm to Present at the Wedbush 2014 Life Sciences Management Access Conference

NEWTON, Mass., Aug. 7, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...
Aug 1, 2014

Karyopharm to Host Second Quarter 2014 Earnings Call on August 7, 2014

NEWTON, Mass., Aug. 1, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on nuclear transport targets, today announced that it...
Jun 30, 2014

Karyopharm Announces Full Exercise of Underwriters Option to Purchase Additional Shares in Public Offering of Common Stock

NATICK, Mass., June 30, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that the underwriters of its previously announced public offering of common stock have...
Jun 26, 2014

Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock

NATICK, Mass., June 26, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced the pricing of its underwritten public offering of 2,647,247 shares of its common stock...
Jun 25, 2014

Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock

NATICK, Mass., June 25, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) today announced that it has commenced an underwritten public offering of 2,200,000 shares of its common...
Jun 24, 2014

Karyopharm Initiates Registration-Directed, Randomized Study of Selinexor (KPT-330) in Older Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

NATICK, Mass., June 24, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel...
Jun 16, 2014

Karyopharm Announces: FDA Considers the Effectiveness and Safety Technical Sections Complete to Support Conditional Approval for the New Animal Drug Application for Verdinexor (KPT-335) to Treat Lymphoma in Client Owned Dogs

NATICK, Mass., June 16, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel,...
Jun 13, 2014

Karyopharm Announces First Combination Data of Selinexor With Low-Dose Dexamethasone in Heavily Pretreated Multiple Myeloma Patients

NATICK, Mass., June 13, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced initial Phase 1 data from patients with...
Jun 9, 2014

Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in Patients with Hormone Refractory Prostate Cancer (SHIP Study)

NATICK, Mass., June 9, 2014 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class...

Show per page

Click here to print this page.
Click here to send us an email.
Click here to subscribe to RSS Feed.